NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance. The cost ...

Erleada (apalutamide) is a brand-name drug prescribed for certain types of prostate cancer in adults. Erleada comes as a tablet that’s typically taken once per day. For these uses, Erleada may ...